Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer
Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager, Appointed Chief Business Officer
Related news for (ZNTL)
- Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
- Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
- Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
- Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
- Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025